|
|
|
|
| Join this live discussion designed for scientists and leaders seeking to understand where open-source AI is delivering real impact today—and why AI is no longer optional for staying competitive in drug discovery. Registration is free, more info here. |
|
|
|
|
By Ashley Zehnder, Fauna Bio | Examining natural mechanisms of cardiac repair in hibernating squirrels has provided insight into biological pathways that could help develop a therapeutic for HFpEF. | |
|
|
Charting The Future Of Antimicrobial Resistance | A conversation with Ajit Parhi, Ph.D., TAXIS Pharmaceuticals | We caught up with Ajit Parhi, Ph.D., CSO of TAXIS Pharmaceuticals, to discuss policy, precision science, and AI in battling antimicrobial resistance. |
|
|
|
| Meeting The Challenge Of Rising API Complexity | Webinar | Lonza | Review award-winning AI and vast data that propel a leading predictive retrosynthesis technology and how Lonza tailored its performance to suit the needs of process chemists in Preclinical Route Design. |
|
|
| A Pragmatic Approach To Developing A Rare Disease Drug | White Paper | Curia | We are beginning to see a rise in the interest of developing “orphan drugs.” Examine challenges and considerations associated with the expedited development and how to successfully work through them. |
|
|
|
|
|
|
|
|
